{ "slug": "ovarian-cancer", "question": "What are the odds of developing ovarian cancer?", "category": "cancer", "no_reliable_estimate": false, "perceived": { "description": "Ovarian cancer occupies a disproportionate space in the public fear landscape relative to its actual incidence — partly because it is often diagnosed late, partly because the early-detection story is far less reassuring than for breast or cervical cancer. There is no reliable population-level screening test, and the \"silent killer\" framing in media coverage reinforces the sense that the disease strikes without warning. Most women cannot distinguish between the lifetime risk of ovarian cancer (~1%) and the lifetime risk of breast cancer (~13%), and the two are frequently conflated in casual conversation about \"women's cancers.\"\n", "rough_estimate": "Many adults assume ovarian cancer is nearly as common as breast cancer", "kind": "intuition" }, "native": { "display": "~1 in 91 US women lifetime risk of diagnosis", "numerator": 11, "denominator": 1000, "unit": "lifetime", "population": "US women, all ages" }, "normalized": { "lifetime_us_adult": 0.011, "display": "1 in ~91 lifetime (US women)", "log_value": -1.96, "assumptions": "The American Cancer Society estimates a US woman's lifetime risk of developing ovarian cancer at approximately 1 in 91 (~1.1%), based on SEER incidence data. SEER confirms approximately 1.1% of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2021-2023 data. The ACS projects ~21,010 new cases and ~12,450 deaths in 2026. Lifetime risk of dying from ovarian cancer is lower, about 1 in 143 (~0.7%), because roughly 50% of cases are now survived. Point estimate 0.011 for incidence; uncertainty band reflects the range between the death-only figure (~0.007) and older, higher historical incidence estimates (~0.013) before the secular decline driven by oral contraceptive use and reduced hormone therapy.\n", "uncertainty": { "low": 0.008, "high": 0.013 }, "scope": "subgroup_lifetime" }, "sources": [ { "url": "https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html", "title": "Key Statistics for Ovarian Cancer", "publisher": "American Cancer Society", "source_type": "reputable_reference", "statistic": "Lifetime risk ~1 in 91; ~21,010 new cases and ~12,450 deaths projected for 2026", "excerpt": "\"A woman's risk of getting ovarian cancer during her lifetime is about 1 in 91. Her lifetime chance of dying from ovarian cancer is about 1 in 143. [...] The American Cancer Society estimates that in 2026, about 21,010 new cases of ovarian cancer will be diagnosed and 12,450 women will die of ovarian cancer in the United States.\"\n", "source_date": "2026-01-13", "source_accessed": "2026-04-24", "archive_url": "https://web.archive.org/web/20260426204640/https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html", "calculation_notes": "ACS gives lifetime incidence directly as ~1 in 91 (~1.1%) and lifetime mortality as ~1 in 143 (~0.7%). The headline figure used here is incidence, not mortality, because the question asks about developing ovarian cancer, not dying from it. The ~60% case-fatality implied by the ratio (0.7/1.1) is considerably higher than for breast cancer (~18%), reflecting later-stage diagnosis on average and the absence of an effective screening test.\n", "independence_note": "ACS derives its lifetime-probability figures from SEER incidence and mortality data (NCI). Treat as partially dependent with the SEER source below.\n" }, { "url": "https://seer.cancer.gov/statfacts/html/ovary.html", "title": "Cancer Stat Facts: Ovarian Cancer", "publisher": "National Cancer Institute / SEER Program", "source_type": "govt_report", "statistic": "Approximately 1.1% of women will be diagnosed with ovarian cancer at some point during their lifetime", "excerpt": "\"Approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2021–2023 data.\"\n", "source_date": "2025-04-17", "source_accessed": "2026-04-24", "archive_url": "https://web.archive.org/web/20260426204715/https://seer.cancer.gov/statfacts/html/ovary.html", "calculation_notes": "SEER provides the upstream population-registry data from which ACS derives its headline figures. The 1.1% lifetime risk is consistent with the ACS \"1 in 91\" figure. Five-year relative survival for ovarian cancer is approximately 51%, far lower than for breast cancer (91.7%), which is why the diagnosis-to-death gap is narrower here.\n", "independence_note": "SEER is the upstream data source that ACS cites; treat these two as partially dependent. SEER is included as the authoritative primary-pipeline citation.\n" } ], "comparison_anchors": [ { "label": "Breast cancer diagnosis (lifetime, US women)", "lifetime_us_adult": 0.13 }, { "label": "Cervical cancer diagnosis (lifetime, US women)", "lifetime_us_adult": 0.006 }, { "label": "Lung cancer diagnosis (lifetime, US)", "lifetime_us_adult": 0.063 }, { "label": "Any cancer death (lifetime, US)", "lifetime_us_adult": 0.14 } ], "regional_breakdown": [ { "region": "US women (all races)", "probability": 0.011, "notes": "ACS/SEER: ~1 in 91 lifetime incidence" }, { "region": "US White women", "probability": 0.012, "notes": "Slightly higher age-adjusted incidence than Black women" }, { "region": "US Black women", "probability": 0.009, "notes": "Lower incidence but higher case-fatality and later-stage diagnosis on average" } ], "personal_factor_multipliers": [ { "factor": "BRCA1 pathogenic variant", "multiplier": 35, "notes": "Lifetime ovarian cancer risk ~39-44% vs ~1.1% baseline; the sharpest single risk elevation" }, { "factor": "BRCA2 pathogenic variant", "multiplier": 15, "notes": "Lifetime ovarian cancer risk ~11-17% vs ~1.1% baseline" }, { "factor": "First-degree family history of ovarian cancer", "multiplier": 3, "notes": "Aggregate figure across population studies" }, { "factor": "Long-term oral contraceptive use (5+ years)", "multiplier": 0.5, "notes": "Oral contraceptive use reduces ovarian cancer risk by roughly 50%; protective effect persists for decades after cessation" } ], "short_label": "Ovarian cancer", "myth_framing": "overrated", "outcome_severity": "serious_harm", "exposure_pattern": "recurring", "outcome_type": "chronic_illness", "valence": "negative", "caveats": "This entry is lifetime *incidence* (diagnosis), not mortality. Ovarian cancer's case-fatality rate is high compared to other gynecological cancers — roughly 60% of women diagnosed will eventually die of the disease — because no effective population screening test exists and most cases are diagnosed at advanced stage. The \"silent killer\" label is partly earned: early-stage symptoms are nonspecific and easily attributed to other causes. However, the baseline lifetime risk of developing ovarian cancer (~1 in 91) is roughly 12x lower than the equivalent figure for breast cancer (~1 in 8), a gap many people do not appreciate.\n", "quality_score": { "d1": 4, "d2": 4, "d3": 5, "d4": 4, "d5": 5, "d6": 5, "d7": 4, "d8": 5, "avg": 4.5, "scored_by": "extracted-from-transcript", "scored_at": "2026-05-03", "methodology_version": "1.0" }, "reviewer": "8d-eval-2026-05-16", "last_reviewed": "2026-05-16", "reviewed": true, "generated_at": "2026-04-24", "image": { "alt": "Two concentric pale ovals on a muted lavender-grey background, flat vector illustration suggesting quiet symmetry." }, "attribution": "Likelier — https://likelier.app", "license": "https://creativecommons.org/licenses/by-sa/4.0/", "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single", "canonical_url": "https://likelier.app/ovarian-cancer" }